The aim of the present study was therefore to assess the effects of letrozole on the proliferation marker Ki67 and receptors for oestrogen and progesterone by immunohistochemical assessment in serial biopsies from primary breast cancers taken before, at 10–14 days and at 3 months into treatment. Here, MKI67 is linked to breast cancer.